Consistently, there is no significant difference in the immune cells, including CD4, CD8 T cells and DCs from the tumor or tumor-draining lymph nodes between Gpr84+/+ and Gpr84CKO(Supplemental 4J–L). This evidence concerns the gene CD4 and neoplasm.